External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home EULAR 2025
Roche and Genentech at

EULAR 2025

June 11 - June 14
Barcelona, Spain
congress.eular.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
02:30 PM
Duration 90mins Barcelona
Obinutuzumab demonstrates consistent benefit across numerous primary endpoint definitions using REGENCY study results of patients with active lupus nephritis
Rovin BH, Pendergraft III WF, Lightstone L, Amoura Z, Furie RA, Hassan I, Yoo B, Martins E, Hans A-C, Omachi TA, Schindler T, Garg JP, Henes J, Malvar A
Nephrology - Immunology - Rheumatology | Lupus nephritis

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
07:30 AM
Duration 60mins Barcelona, Spain
Severe COVID-19 amongst patients with systemic lupus erythematosus and lupus nephritis between 2020 and 2024: a retrospective cohort study using US-based electronic health records
Lindsay L, Trinh H, Wang S, Pendergraft III WF, Kirchner P, Yazdany J
Nephrology - Rheumatology - Immunology | Lupus nephritis - Systemic Lupus Erythematosus

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:30 PM
Duration 75mins Barcelona, Spain
Full Symposium: Advances in lupus nephritis: what’s next?
Edward Vital, Johanna Mucke, Richard Furie, Ana Malvar
Nephrology - Rheumatology - Immunology | Lupus nephritis

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
07:30 AM
Duration 60mins Barcelona, Spain
Kidney-related outcomes with obinutuzumab in patients with active lupus nephritis: a pre-specified exploratory analysis of the REGENCY study
Rovin BH, Garg JP, Lightstone L, Daugas E, Furie RA, Omachi T, Hassan I, Martins E, Schindler T, Pendergraft III WF, Quintana L, Leszczynski P, Malvar A
Nephrology - Rheumatology - Immunology | Systemic Lupus Erythematosus

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 60mins Barcelona, Spain
Obinutuzumab shows promise in lupus nephritis regardless of baseline serological biomarkers: an exploratory post hoc analysis of the phase II NOBILITY study
Vital EM, Vargas B, Rae J, Wang T, Hackney J, Looney CM, Pendergraft III WF, Lightstone L, Rovin BH, Furie RA, Raghu H
Nephrology - Rheumatology - Immunology | Lupus nephritis

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
08:15 AM
Duration 90mins Barcelona, Spain
A Phase Ib, multicentre, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneously administered mosunetuzumab▼ in participants with systemic lupus erythematosus
Chindalore VL, Martins E, Pendergraft III WF, Sheng R, Schroeder A, Gearhart L, Mody H, Mao A, Garg JP, Dankiewicz-Fares I, Agachi S
Nephrology - Rheumatology - Immunology | Systemic Lupus Erythematosus

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 90mins Barcelona, Spain
Interim population pharmacokinetic analysis of obinutuzumab in adolescents with active class III or IV lupus nephritis and simulations to determine obinutuzumab dose selection in a younger paediatric cohort aged 5 to <12 years in the POSTERITY clinical study
Cossin V, Meneses-Lorente G; D'Arienzo V, Lanza B, Van Someren C, Wood N, Lehane PB
Nephrology - Rheumatology - Immunology | Lupus nephritis

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.